Genen­tech and Bio­gen pen roy­al­ty deal for blood can­cer drug with big po­ten­tial

Bio­gen’s col­lab­o­ra­tion with Genen­tech could pay off again in the form of US roy­al­ties for the po­ten­tial blood can­cer drug glofi­ta­m­ab, a CD20xCD3 bis­pe­cif­ic.

Bio­gen will re­ceive tiered roy­al­ties on po­ten­tial net sales of glofi­ta­m­ab with­in the US and will have no pay­ment oblig­a­tions — if the drug gets ap­proved. Tiered roy­al­ties will be “in the mid-sin­gle dig­its range on po­ten­tial net sales of glofi­ta­m­ab” in the US, Bio­gen said, but Genen­tech, a mem­ber of Roche, large­ly re­tains com­mer­cial con­trol.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER